nach oben

Erschienen in:

06.12.2019 | Clinical trial

Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older

verfasst von: Min Hwan Kim, Gun Min Kim, Jee Hung Kim, Jee Ye Kim, Hyung Seok Park, Seho Park, Young Up Cho, Byeong Woo Park, Seung Il Kim, Joohyuk Sohn

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

An antibody–drug conjugate targeting HER2, DS8201, has shown clinical activity against breast cancer with low-level HER2 expression. We aimed to evaluate the prognostic impact of intermediate HER2 expression in estrogen receptor (ER)+ early breast cancer (EBC) and metastatic breast cancer (MBC) cohorts.

Methods

We analyzed prospectively collected data from EBC and MBC cohorts at Yonsei Cancer Center. Patients with HER2 immunohistochemistry (IHC) 0 ~ 1+ were assigned to the HER2-negative group, and patients with IHC 2+ and in situ hybridization (ISH)-negativity were assigned to the HER2-intermediate group. After the exclusion of HER2 IHC 3+ or ISH+ patients, a total of 2657 EBC and 535 MBC patients were analyzed.

Results

In total, 654 (24.6%) EBC and 166 (31.0%) MBC patients were classified in the HER2-intermediate group. The HER2-intermediate patients more frequently tended to have progesterone receptor (PR)-negativity and higher nuclear grade in the EBC cohort, and showed a higher proportion of patients aged ≥ 55 years compared with the HER2-negative group in the MBC cohort. The HER2-intermediate patients showed significantly poorer recurrence-free survival (RFS) compared to the HER2-negative patients in the EBC cohort (p = 0.044). Notably, intermediate HER2 expression predicted poorer RFS in EBC patients aged ≥ 55 years (hazard ratio 1.95; p = 0.042) in multivariate Cox analysis but did not affect RFS in those aged < 55 years. In line with the EBC cohort results, intermediate HER2 expression predicted poorer overall survival (OS) in MBC patients aged ≥ 55 (hazard ratio 1.45; p = 0.044) without affecting OS of those aged < 55 years.

Conclusion

Intermediate HER2 expression is an independent predictor of poor prognosis in both ER+ EBC and MBC patients aged ≥ 55 years. The clinical efficacy of new HER2-targeting antibody–drug conjugates needs to be validated in this high-risk subset of ER+ breast cancer patients.

Nur mit Berechtigung zugänglich

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. https://doi.org/10.1038/35021093 CrossRefPubMed

Borg A, Tandon AK, Sigurdsson H et al (1990) HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50(14):4332–4337PubMed

Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684. https://doi.org/10.1056/NEJMoa052122 CrossRefPubMed

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. https://doi.org/10.1056/NEJM200103153441101 CrossRefPubMed

Swain SM, Baselga J, Kim SB et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734. https://doi.org/10.1056/NEJMoa1413513 CrossRefPubMedPubMedCentral

Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743. https://doi.org/10.1056/NEJMoa064320 CrossRefPubMed

Fehrenbacher L, Cecchini RS, Geyer CE et al (2018) NSABP B-47 (NRG oncology): phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Cancer Res. https://doi.org/10.1158/1538-7445.SABCS17-GS1-02 CrossRef

Arpino G, Wiechmann L, Osborne CK et al (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29(2):217–233. https://doi.org/10.1210/er.2006-0045 CrossRefPubMedPubMedCentral

Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96(12):926–935. https://doi.org/10.1093/jnci/djh166 CrossRefPubMed

10.

Gilcrease MZ, Woodward WA, Nicolas MM et al (2009) Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol 33(5):759–767. https://doi.org/10.1097/PAS.0b013e31819437f9 CrossRefPubMedPubMedCentral

11.

Ignatov T, Eggemann H, Burger E et al (2015) Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. Breast Cancer Res Treat 151(2):357–364. https://doi.org/10.1007/s10549-015-3407-2 CrossRefPubMed

12.

Eggemann H, Ignatov T, Burger E et al (2015) Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer 22(5):725–733. https://doi.org/10.1530/ERC-15-0335 CrossRefPubMed

13.

Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. https://doi.org/10.1056/NEJMoa041588 CrossRefPubMed

14.

Schalper KA, Kumar S, Hui P et al (2014) A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med 138(2):213–219. https://doi.org/10.5858/arpa.2012-0617-OA CrossRefPubMed

15.

Ogitani Y, Aida T, Hagihara K et al (2016) DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22(20):5097–5108. https://doi.org/10.1158/1078-0432.CCR-15-2822 CrossRefPubMed

16.

Iwata H, Tamura K, Doi T et al (2018) Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: long-term results of a large phase 1 study with multiple expansion cohorts. J Clin Oncol 36(15_suppl):2501. https://doi.org/10.1200/JCO.2018.36.15_suppl.2501 CrossRef

17.

Hausman DF, Hamilton EP, Beeram M et al. (2017) Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers. J Clin Oncol. https://doi.org/10.1200/JCO.2017.35.4_suppl.TPS215 CrossRef

18.

Carlomagno C, Perrone F, Gallo C et al (1996) c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14(10):2702–2708. https://doi.org/10.1200/JCO.1996.14.10.2702 CrossRefPubMed

19.

De Laurentiis M, Arpino G, Massarelli E et al (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11(13):4741–4748. https://doi.org/10.1158/1078-0432.CCR-04-2569 CrossRefPubMed

20.

Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36(20):2105–2122. https://doi.org/10.1200/JCO.2018.77.8738 CrossRefPubMed

21.

Leong SP, Shen ZZ, Liu TJ et al (2010) Is breast cancer the same disease in Asian and Western countries? World J Surg 34(10):2308–2324. https://doi.org/10.1007/s00268-010-0683-1 CrossRefPubMedPubMedCentral

22.

Giuliano M, Trivedi MV, Schiff R (2013) Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care (Basel) 8(4):256–262. https://doi.org/10.1159/000354253 CrossRef

23.

Miller TW, Hennessy BT, Gonzalez-Angulo AM et al (2010) Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120(7):2406–2413. https://doi.org/10.1172/JCI41680 CrossRefPubMedPubMedCentral

24.

Guo S, Sonenshein GE (2004) Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 24(19):8681–8690. https://doi.org/10.1128/MCB.24.19.8681-8690.2004 CrossRefPubMedPubMedCentral

25.

Creighton CJ, Hilger AM, Murthy S et al (2006) Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66(7):3903–3911. https://doi.org/10.1158/0008-5472.CAN-05-4363 CrossRefPubMed

26.

Lee AV, Cui X, Oesterreich S (2001) Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 7(12 Suppl):4429s–4435s (Discussion 4411s-4412s)PubMed

27.

Pietras RJ, Marquez-Garban DC (2007) Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 13(16):4672–4676. https://doi.org/10.1158/1078-0432.CCR-07-1373 CrossRefPubMed

28.

Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. https://doi.org/10.1056/NEJMoa1109653 CrossRefPubMed

29.

Andre F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929–1940. https://doi.org/10.1056/NEJMoa1813904 CrossRefPubMed

30.

Johnston S, Pippen J Jr, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27(33):5538–5546. https://doi.org/10.1200/JCO.2009.23.3734 CrossRefPubMed

31.

Kaufman B, Mackey JR, Clemens MR et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27(33):5529–5537. https://doi.org/10.1200/JCO.2008.20.6847 CrossRefPubMed

32.

Martin M, Holmes FA, Ejlertsen B et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688–1700. https://doi.org/10.1016/S1470-2045(17)30717-9 CrossRefPubMed

33.

Anders CK, Johnson R, Litton J et al (2009) Breast cancer before age 40 years. Semin Oncol 36(3):237–249. https://doi.org/10.1053/j.seminoncol.2009.03.001 CrossRefPubMedPubMedCentral

34.

Azim HA Jr, Michiels S, Bedard PL et al (2012) Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 18(5):1341–1351. https://doi.org/10.1158/1078-0432.CCR-11-2599 CrossRefPubMed

35.

Sparano JA, Gray RJ, Makower DF et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121. https://doi.org/10.1056/NEJMoa1804710 CrossRefPubMedPubMedCentral

36.

Diab SG, Elledge RM, Clark GM (2000) Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92(7):550–556. https://doi.org/10.1093/jnci/92.7.550 CrossRefPubMed

Titel: Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older
verfasst von: Min Hwan Kim
Gun Min Kim
Jee Hung Kim
Jee Ye Kim
Hyung Seok Park
Seho Park
Young Up Cho
Byeong Woo Park
Seung Il Kim
Joohyuk Sohn
Publikationsdatum: 06.12.2019
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05505-4

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients

Paget’s disease of the nipple in a Her2-positive breast cancer xenograft model

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies

Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice

Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis

Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment?

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie